
Emergent BioSolutions (EBS) Stock Forecast & Price Target
Emergent BioSolutions (EBS) Analyst Ratings
Bulls say
Emergent BioSolutions Inc has recently secured multiple contract modification awards, highlighting its strong position in the biodefense and infectious disease control sectors. A notable contract modification of $30 million from the Biomedical Advanced Research and Development Authority (BARDA) reinforces the company's financial stability and growth potential. These developments underline the value of Emergent's diverse product portfolio, primarily driven by its commercial segment, which emphasizes the positive outlook for the company's stock.
Bears say
Emergent BioSolutions Inc faces several significant risks that contribute to a negative outlook on its stock, including the potential for accelerated erosion of the NARCAN franchise due to increasing generic competition, which is critical for revenue generation. Additionally, the company may struggle to secure crucial government contracts for its medical countermeasures (MCMs) segment, thereby limiting its revenue potential from this important area. Lastly, the company has recognized impairments of long-lived assets, totaling $27.2 million, which further highlights financial vulnerabilities that could adversely affect future performance.
This aggregate rating is based on analysts' research of Emergent BioSolutions and is not a guaranteed prediction by Public.com or investment advice.
Emergent BioSolutions (EBS) Analyst Forecast & Price Prediction
Start investing in Emergent BioSolutions (EBS)
Order type
Buy in
Order amount
Est. shares
0 shares